Comparative, Randomized, Open Label, Parallel, Multicentric study for Efficacy and Safety of Lornoxicam + Chlorzoxazone versus Lornoxicam in the Management of Acute Musculoskeletal Pain.

Hetero Labs Limited0 个研究点目标入组 240 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•a)Male or female patients, b)Between 20-65 years of age,
•c)Willing to give written informed consent and willing to comply with trial protocol. d)Out patients with diagnosis of cervical spondylosis. e) Patients with at least 40 mm pain rating on VAS scale. f) Patient and / or physician?s global assessment of arthritic condition as fair, poor or very poor. g)Patients not on any anti-inflammatory or other therapy in the past 2 weeks known to affect the study outcome.

•a) Pregnant and lactating women b) Patients with H/O any drug allergy c) Unwilling to comply with the protocol requirements d) Patients with gastro-intestinal disease, peptic ulcer, bleeding disorder and fecal blood loss. e) Patients with cardiac, hepatic, renal dysfunction and haemopoetic disorder f) Patients with hypertension g) Patients deemed ineligible by the investigator h)H/O skin lesions, skin ulcers

发起方